Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 440
- Registration Number
- NCT00000885
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00005762
- Locations
- 🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00001086
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Stanford Univ Med Ctr, Stanford, California, United States
🇺🇸Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 300
- Registration Number
- NCT00005017
- Locations
- 🇺🇸
Jaime Hernandez, Research Triangle Park, North Carolina, United States
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 60
- Registration Number
- NCT00002227
- Locations
- 🇺🇸
The Whitman Walker Clinic, Washington, District of Columbia, United States
🇺🇸Richard Elion, Washington, District of Columbia, United States
🇺🇸Montrose Clinic, Houston, Texas, United States
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00002235
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸Pacific Oaks Med Group, Beverly Hills, California, United States
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002234
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002419
- Locations
- 🇺🇸
Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pacific Oaks Med Group, Beverly Hills, California, United States
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00006208
- Locations
- 🇺🇸
East Bay Clinical Trial Ctr, Concord, California, United States
🇺🇸Orange Coast Med Group, Newport Beach, California, United States
🇺🇸Health Positive, Safety Harbor, Florida, United States
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 400
- Registration Number
- NCT00011895
- Locations
- 🇺🇸
Therapeutic Concepts, Houston, Texas, United States
🇺🇸Diversified Med Practices, PA, Houston, Texas, United States
🇺🇸Infectious Diseases Associates of Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.